Screen-Shot-2017-08-17-at-2.05.30-PM-002-e1503070600829.png

Paxeon Reconstruction Successfully Launches 135º Collared High Offset HA Hip Stem

Posted On August 18, 2017 By OrthoSpineNews In Recon, Top Stories /

Paxeon Reconstruction, a manufacturer of best-in-class orthopedic products including derivative and emerging products, announces that has successfully launched its High Offset (135º) Collared Origin HA Coated THA Stem.

Paxeon Reconstruction now offers the following options in it’s Origin HA THA Stem – 135º Standard Collared and Collarless, 135º High Offset Collared and Collarless, 125º Coxa Vara Collared – giving Paxeon Reconstruction 5 options (3 Collared, 2 Collarless) on its Origin Hip System.

“The goal in hip replacement is to restore the prediseased biomechanics of the hip. Paxeon has released a lateralized collared stem which gives the surgeon an option to restore the native offset without lateralizing the center of rotation of the hip. Paxeon has been very receptive in meeting the surgeons needs as demonstrated by bringing the lateralized collared stem to market” said Dr. Brian Rosenberg.

Kyle Sineath, President of Paxeon Reconstruction said: “The addition of a 135º Collared High Offset to our already proven hip implants is exciting for Paxeon. We strive to provide a complete portfolio for our successful Value Solutions Program to extend savings throughout the total joint continuum of care.”

“I am very pleased that Paxeon Reconstruction has addressed a specific need in total hip arthroplasty by producing the first truly collared lateral offset stem with impaction broaching technique using their Origin hip stem. This new stem allows flexibility in hip arthroplasty that was previous unavailable in any stem using impaction broaching technique. It allows surgeons to adjust offset without changing neck angles or leg length so that we can better match the patient’s normal anatomy. This is just another example of Paxeon Reconstruction responding to surgeon needs in leading the way in total joint reconstruction innovation” said Dr. Kevin Pugh.

About Paxeon Reconstruction

Paxeon Reconstruction builds best-in-class orthopaedic products, including derivative and emerging products. We collaborate with hospitals, health systems and physicians to create alignment and utilization of value-based solutions combined with efficiency models for today’s changing healthcare environment. Paxeon Reconstruction offer the world’s most comprehensive portfolio of orthopaedic products and services for joint reconstruction. Paxeon Reconstruction has a celebrated clinical history, and has evolved to meet the needs of the changing orthopaedics marketplace. The history that weaves the fabric of the Paxeon Reconstruction is one that is rich with innovation and demonstrates sustained leadership in an ever-changing landscape of patient and professional needs.

The New York Cosmos Announce Partnership With Hospital for Special Surgery (HSS)

Posted On August 18, 2017 By OrthoSpineNews In Sports Medicine /

NEW YORK, Aug. 16, 2017 /PRNewswire-USNewswire/ — The New York Cosmos announced today that Hospital for Special Surgery (HSS) will be the team’s official hospital. The new multi-year partnership provides the Cosmos access to one of the world’s leading centers for orthopedics and sports medicine. With this partnership, the Cosmos have officially named HSS physician Danyal H. Nawabi, M.D., as the Medical Director/Head Orthopedic surgeon for the team.

“Hospital for Special Surgery is a world leader in orthopedic care and the New York Cosmos are proud to enter into a partnership with them,” said Cosmos Chief Operating Officer, Erik Stover. “With Dr. Nawabi serving as the team’s Medical Director, we are ensuring that our players will receive nothing but the best medical coverage to help maintain a healthy team and provide a quick return to the field when injuries occur.”

“I’ve had the great experience of being involved with the English Premier League and Major League Soccer, and have always had an affinity for the game of soccer and a passion for caring for high performance athletes,” said Dr. Nawabi. “Now as a sports medicine surgeon at HSS it’s my privilege to oversee player care for the New York Cosmos and work with athletic trainers and coaches to keep the team safe and performing optimally on the field.”

Dr. Nawabi is an attending orthopedic surgeon on the Sports Medicine Service at HSS, specializing in knee, shoulder, and hip surgery, performing both arthroscopic and joint replacement surgeries. He completed his medical training at Oxford University in England and residency in orthopedic surgery on the prestigious Percivall Pott Rotation in London. Dr. Nawabi completed his fellowship in sports medicine at HSS and received additional training in sports knee and shoulder surgery while treating elite soccer athletes from the English Premier League and the MLS, including stints with Chelsea FC, West Ham FC, and the New York Red Bulls.

Dr. Nawabi will be joined by fellow HSS colleagues Brett Toresdahl, M.D., primary care sports medicine physician, and Mark Drakos, M.D., foot and ankle surgeon, who will serve as team physicians for the Cosmos. Together, they will provide orthopedic consultation services and oversee the rehabilitation of sports injuries and conditions at the Cosmos’ training facility, as well as at their home field, MCU Park, in Brooklyn.

HSS has been ranked the No. 1 hospital in the country for orthopedics for the eighth consecutive year by U.S. News & World Report. Doctors and therapists from HSS have the distinction of being the team physicians and athletic trainers for some of the most recognized professional sports teams and organizations including the Brooklyn Nets, the New York Knicks, the New York Giants, the New York Mets, the New York Rangers, the New York Red Bulls, UFC, USA Basketball and the FIFA Medical Centre of Excellence among many others.

About The New York Cosmos
The New York Cosmos are the reigning champions of the NASL and the most recognized American soccer brand in the world. Since beginning play at Yankee Stadium in 1971, the iconic club has won a record total of 8 professional soccer championships and brought some of the biggest stars in international soccer to the USA including Pelé, Franz Beckenbauer, Giorgio Chinaglia, Carlos Alberto, and more recently, Raúl and Marcos Senna. With the move to MCU Park in Brooklyn’s historic Coney Island district for the 2017 season, the Cosmos are now based within New York City for the first time in 41 years. For more information on the New York Cosmos, please visit nycosmos.com, join us on Facebook and follow us on Twitter and Instagram (@NYCosmos).

About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 3 in rheumatology by U.S. News & World Report (2017-2017), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital’s research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. HSS has locations in New York, New Jersey and Connecticut.
www.hss.edu

SOURCE Hospital for Special Surgery

AAOS Commends CMS for Important Changes to Bundled Payment Models

Posted On August 17, 2017 By OrthoSpineNews In Financial, Recon /

August 16, 2017 – AAOS

Washington, DC–Yesterday, the Centers for Medicare & Medicaid Services (CMS) announced a proposed rule that addresses significant concerns raised by the American Association of Orthopaedic Surgeons (AAOS) related to mandatory bundled payment programs. First, the proposed rule would reduce the number of mandatory geographic areas participating in the Center for Medicare and Medicaid Innovation’s Comprehensive Care for Joint Replacement (CJR) model from 67 to 34. In addition, the proposed rule would allow CJR participants in the 33 remaining areas to participate on a voluntary basis. CMS also proposes to make participation in the CJR model voluntary for ALL low volume and rural hospitals in all of the CJR geographic areas. Finally, CMS is proposing to cancel the Surgical Hip and Femur Fracture Treatment (SHFFT) payment model and others that were scheduled to begin on January 1, 2018.

AAOS commends CMS for this important proposal and, after further analyzing all details in the rule, AAOS will be submitting comments by the October 16 due date.

READ THE REST HERE

Medovex Corporation Names Charlie Farrahar Chief Financial Officer

Posted On August 17, 2017 By OrthoSpineNews In Spine, Top Stories /

ATLANTA, GA–(Marketwired – Aug 17, 2017) – Medovex Corp. (NASDAQ: MDVX) (“Medovex” or the “Company”), the developer of the DenerveX™ System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to back pain, today reported it has named Charlie Farrahar as its Chief Financial Officer.

Charlie Farrahar is a Certified Public Accountant with over 30 years of managerial finance, administration, human resource and risk management experience in the public, private and non-profit sectors. Mr. Farrahar was the first Chief Financial officer of the Company from its inception through IPO. He remained with the Company as its Secretary only from January 2015 until August 2017, when he agreed to resume the CFO role.

Mr. Farrahar currently serves as Chief Financial Officer for several small private biotech companies in the research and development stage. In 2003 he joined a private governmental assistance startup as it’s CFO and Director of Human Resources, helping with the sale of that company to a private entity in 2011 after it had grown to a multi-state operation with over 400 employees. In the late 1990’s he was CFO of Credit Depot Corp. (Nasdaq).

At its August 16, 2017 quarterly Board meeting, the Board asked Charlie Farrahar, Company Secretary, to become Chief Financial Officer, a role he held from the inception of the Company through its initial public offering. Jeffery Wright, the former CFO, agreed to become the Company’s first Controller.

Jarrett Gorlin, Medovex Chief Executive Officer, stated, “We’re excited by the enthusiastic reception we’ve seen thus far to the Denervex product and realize that we have to properly support sustained revenue growth. One area affected by this growth is the financial/accounting function. With the addition of overseas sales and all the administration that entails, we were no longer able to have just one full-time person in the finance area.”

Gorlin continued, “We asked Charlie Farrahar to become CFO so Jeff Wright could focus on assisting our sales and distribution efforts as we expand sales into multiple countries. They have complementary skill sets and work well together. Their combined experience should allow us to properly steward anticipated growth associated with the launch of a successful new product targeting a broad audience.”

The Company’s DenerveX System recently received CE Mark approval and clearance for commercialization in the European countries and offers a unique way to perform a Facet Joint Syndrome treatment.

Facet Joint Syndrome (FJS), also known as spinal osteoarthritis, spinal arthritis, or facet joint osteoarthritis, is a significant health and economic problem in the United States and other countries in the EU and Rest of World affecting millions each year. Current treatment options are generally temporary and there is no proven long-lasting option for FJS.

The DenerveX System is a highly differentiated technology. It denervates and removes capsular tissue from the Facet Joint in one single procedure. Treatment results from the combined effect of a deburring or polishing action and RF ablation treatment on the Facet Joint. Using this new technique, the slowly rotating burr removes the targeted facet joint synovial membrane and joint surface while the heat ablation destroys tissue and denudes any residual nervous and synovial membrane overlying the joint, removing the end point sensory tissue of the joint.

The DenerveX System consists of the DenerveX Kit which contains the DenerveX Device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is not yet FDA cleared.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company’s first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT INFORMATION

CONTACT INFORMATION
Medovex Corp.
Jason Assad
470-505-9905
Email Contact

Magnetic Fields to Destroy Bacteria on Artificial Joints

Posted On August 17, 2017 By OrthoSpineNews In Recon, Top Stories /

CONN HASTINGS, MedGadget / August 9th, 2017

Scientists at UT Southwestern Medical Center have developed a new technique using high-frequency alternating magnetic fields to heat artificial joints in the body and destroy bacterial films on their surfaces.

Bacterial infections on artificial joints used in knee and hip replacements are a common and serious complication. The bacteria tend to form slimy films on the metal surfaces of the joints called biofilms, and they are difficult to treat using antibiotics.

Dr. David Greenberg, of UT Southwestern Medical Center, describes the solution the researchers developed. “We were looking for better ways to target and treat biofilms,” he says. “Our idea was to put a coil around the joint and run a current through it to create alternating magnetic fields. Human tissue isn’t conductive but metal is, so only the implant would heat up.” The principle is the same as that in induction cooktops, which use magnetic fields to heat metal pots for cooking.

READ THE REST HERE

GLOBUS MEDICAL ANNOUNCES FDA 510(K) CLEARANCE FOR EXCELSIUS GPS™

Posted On August 17, 2017 By OrthoSpineNews In Regulatory, Robotics, Top Stories /

AUDUBON, Pa., Aug. 17, 2017 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that the Excelsius GPS™, a revolutionary robotic guidance and navigation system, has been 510(k) cleared by the U.S. Food and Drug Administration. This platform technology supports minimally invasive and open orthopedic and neurosurgical procedures, with screw placement applications in spine and orthopedic surgery. Excelsius GPS™ seamlessly integrates Globus Medical implants and instruments and is compatible with pre-operative CT, intra-operative CT and fluoroscopic imaging modalities. The system is designed to minimize radiation exposure, streamline workflow, and reproducibly assist in implant placement.

“Excelsius GPS™ is the culmination of years of research and development efforts and demonstrates Globus Medical’s superior product development capabilities,” said Norbert Johnson, Vice President of Robotics, Imaging, & Navigation. “We believe the Excelsius GPS™ System will advance patient care and provide tangible benefits for surgeons and hospitals in terms of time, accuracy and reduced radiation exposure through the application of robotic and navigation technology in spine and orthopedic surgery.”

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to successfully integrate the international operations acquired from Alphatec, both in general and on our anticipated timeline, our ability to transition Alphatec’s international customers to Globus Medical products, our ability to realize the expected benefits to our results from the Alphatec acquisition, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

CONTACT: Contact:
Daniel Scavilla
Senior Vice President, Chief Financial Officer
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

India introduces price controls for knee implants

Posted On August 16, 2017 By OrthoSpineNews In Financial, Recon, Top Stories /

NEW DELHI, Aug 16 (Reuters) – India has capped prices of orthopaedic knee implants, in the country’s latest move to bring down prices of medical devices.

The introduction of price controls marks the latest step by Prime Minister Narendra Modi’s government to make drugs and medical devices more affordable. In February, it imposed a 75 percent price cut for certain heart stents – wire mesh tubes used to treat blocked arteries, which caused protests among manufacturers.

India’s drug pricing authority said on Wednesday that orthopaedic implants in India had unjustified, unreasonable and irrationally high trade margins, leading to exorbitant pricing.

Ananth Kumar, Minister of Chemicals and Fertilisers, told a news briefing the government had capped knee implant prices “in public interest.”

Kumar said the price of the widely used cobalt chromium knee implant, priced at up to 250,000 rupees ($3,895) at Indian hospitals, would now be capped at 54,720 rupees ($852).

READ THE REST HERE

Stryker’s Spine Division Receives FDA Clearance for Serrato Pedicle Screw

Posted On August 16, 2017 By OrthoSpineNews In Regulatory, Spine, Top Stories /

August 16, 2017

ALLENDALE, N.J.–(BUSINESS WIRE)–Stryker’s Spine division today announced that its Serrato™ Pedicle Screw, intended for use in the non-cervical spine as part of the company’s successful Xia^® 3 Spinal System, has received 510(k) clearance from the U.S. Food and Drug Administration.

Serrato Pedicle Screws feature enhanced serrated cutting flutes, a unique dual-thread pattern with an increased number of leads for rapid insertion, and a patented buttress thread locking mechanism designed to minimize cross threading and splaying of the screw head.^1,2 The screws accommodate a variety of rod diameters and materials to suit the patient’s needs—5.5 and 6.0mm diameter rods in commercially pure titanium, titanium alloy, and Vitallium.

“Pedicle screws have been used for decades with very few changes to their design,” said Bradley Paddock, President of Stryker’s Spine division. “The design innovations incorporated into Serrato reinforce our commitment to making industry-leading investments focused on providing the advanced spinal products and differentiated technologies that our surgeon customers have come to expect.”

Serrato leverages the broad portfolio of the Xia 3 Spinal System, an orthopaedic spinal system comprised of a variety of shapes and sizes of screws, blockers, and hooks that affix several different types of rods and connectors to vertebrae or the spinal column for purposes of stabilization, or corrective action through the application of force.

Intended Use

The Xia 3 Spinal System is intended for use in the non-cervical spine. When used as an anterior/anterolateral and posterior, non-cervical pedicle and non-pedicle fixation system, the Xia 3 Spinal System is intended to provide additional support during fusion using autograft or allograft in skeletally mature patients in the treatment of the following acute and chronic instabilities or deformities: degenerative disc disease, spondylolisthesis, trauma, spinal stenosis, curvatures, tumor, pseudarthrosis, and failed previous fusion. For the full Indications for Use, please refer to the Xia 3 Spinal System Instructions for Use.

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information at www.stryker.com.

References

1. Stryker Patent #6,074,391
2. Stryker Design History File DHF0000016688

Content ID TLSER-PR-1_14675

Contacts

Sullivan & Associates
Barbara Sullivan, 714/374–6174
bsullivan@sullivanpr.com

Global Medical Equipment Markets 2017-2022 – Market is Expected to Reach Over $500 Billion in 2020 – Research and Markets

Posted On August 16, 2017 By OrthoSpineNews In Financial /

August 16, 2017

DUBLIN–(BUSINESS WIRE)–The “Medical Equipment Market Global Report 2017” report has been added to Research and Markets’offering.

The Medical Equipment Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global medical equipment sector.

The global medical equipment market is expected to reach over $500 billion in 2020. One of the key drivers of the medical equipment market include Technology – Technology is expected to be a continued driver of market growth during this period. Areas of particular development are likely to be robotics and minimally invasive surgery technologies. Markets such as this one will benefit from the greater efficiencies offered by these technologies. For example, ConforMIS iFit image-to-implant technology allows surgeons to 3D print joint replacement implants to suit the needs of each patient’s body, thereby reducing the duration of knee replacement surgery as well as patient recovery time.

Use of medical devices for the home based diagnosis and treatment of medical conditions is increasing. Technological developments in devices such as glucose monitors, insulin delivery devices, nebulizers and oxygen concentrators have enabled diagnosis and monitoring of many diseases at home. Remote control technology is also allowing healthcare professionals to support home based treatments which is leading to preference for home and self-care treatment .

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider healthcare market, and compares it with other markets.

Scope:

Markets Covered: Cardiovascular Devices, In-Vitro Diagnostics, Orthopaedic Devices, Ophthalmic Devices, Diagnostic Equipment, Hospital Supplies, Diabetes Care Devices, Patient Monitoring Devices, Anesthesia And Respiratory Devices, Nephrology And Urology Devices, Wound Care Devices, ENT Devices, Neurology Devices, Surgical Equipment, Dental Equipment And Supplies
Companies Mentioned: Medtronic, Johnson & Johnson, GE Healthcare, Siemens Healthcare, and Philips Healthcare
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time Series: Five years historic and forecast
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Medical Equipment Indicators Comparison
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

For more information about this report visit https://www.researchandmarkets.com/research/wzhwph/medical_equipment

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Medical Devices

Renowned Orthopaedic Specialists Publish First Collection of Rebound Bracing Clinical Articles

Posted On August 16, 2017 By OrthoSpineNews In Sports Medicine, Top Stories /

August 15th, 2017

A group of internationally recognized orthopaedic surgeons has published the first collection of clinical cases utilizing Rebound® braces from Össur. The innovative Rebound line includes indication-specific Functional Healing braces designed to optimize patient healing while maintaining function and mobility.

“We are gratified that some of the world’s most respected thought-leaders in orthopaedic surgery have contributed these clinical evaluations of Rebound bracing,” said Dr. Axel Schulz, Medical Director for Össur, the global medical technology leader renowned for its advanced prosthetic and orthopaedic innovations. “Their experience will be very helpful in formulating longer-term clinical protocols for these technologies, which have been specifically designed to help accelerate recovery from PCL, ACL and cartilage-based knee injuries.”

LaPrade Case Demonstrates Rebound PCL’s Effectiveness

The Rebound PCL Brace from Össur is the world’s first dynamic force brace for rehabilitating posterior cruciate ligament (PCL) ruptures. It is part of the Functional Healing® line of innovative indication-specific, dynamic orthopaedic solutions intended to optimize healing while maintaining patient function and mobility.

Össur’s Rebound product family is built on decades of experience and designed to protect bone and soft tissue during healing through innovative technology and proven biomechanical approaches. Rebound PCL, the world’s first and only dynamic force brace for rehabilitating posterior cruciate ligament (PCL) ruptures, reflects the company’s Functional Healing approach to orthopaedic innovation, which focuses on developing proprietary technologies according to specific indication-based protocols and clinically relevant outcomes.

In his case study, Robert LaPrade, M.D., Ph.D., Complex Knee and Sports Medicine Surgeon at The Steadman Clinic, reports that use of the Rebound PCL brace helped aid an adult male gymnast recover after double bundle PCL reconstruction, a complete anatomic posterolateral corner knee reconstruction and a medial meniscus root repair following a severe varus noncontact injury. With full restoration of knee motion and complete healing of his PCL and PCL reconstructions, the patient had an excellent outcome and returned to a national level of competition just one year following his surgery.

According to Dr. LaPrade, PCL reconstruction recovery historically tends to stretch out over time due to the effects of gravity, but the Rebound PCL brace “negates the negative effects of gravity by applying an anterior translation force at higher knee flexion angles,” thereby protecting the PCL graft in early post-op applications.

“Patients with serious multiple ligament knee injuries can be restored back to high levels of activity with modern anatomic-based reconstructions. The additional use of the Rebound PCL brace facilitates a safe initiation of knee motion in the early postoperative period,” he concluded.

Other renowned clinicians who have contributed cases to the Rebound Bracing collection include:

Dr. Mats Brittberg, Professor, Region Halland Orthopedics at Kungsbaca Hospital, Sweden
Dr. Tobias Jung, Senior Physician, Section Head Knee Surgery and Sports Traumatology at Charité-University Medicine Berlin, Germany
Dr. Christos Kondogiannis, Orthopaedic Surgeon at Royal Melbourne Hospital St. Vincent’s Private Hospitals, Australia
Dr. Thomas Stein, Executive Senior Physician in the Department for Sport Traumatology at Berufsgenossenschaftliche Unfalklinik Frankfurt am Main, Germany
Dr. Peter Verdonk, full knee specialist at the Antwerp Orthopaedic Center, Department of Orthopaedic Surgery at Antwerp University Hospital, Netherlands

The full collection of Rebound case studies is available online at https://www.ossur.com/rebound.

“The clinical community’s response to the current line of Rebound braces has been so overwhelmingly positive that we look forward to introducing additional Rebound products in the future, which will complement our Functional Healing products in the continuum of care,” Dr. Schulz said.

Month: August 2017

CONTACT INFORMATION

Contacts

Contacts

LaPrade Case Demonstrates Rebound PCL’s Effectiveness